Crinetics Pharmaceuticals (NASDAQ:CRNX) reported quarterly losses of $(1.23) per share which beat the analyst consensus estimate of $(1.25) by 1.6 percent. This is a 18.27 percent decrease over losses of $(1.04) per share from the same period last year. The company reported quarterly sales of $10.306 million which beat the analyst consensus estimate of $8.512 million by 21.08 percent. This is a 2.75K percent increase over sales of $361.000 thousand the same period last year.